Adalimumab induced psoriasis in Crohn’s disease and treatment with ustekinumab: case report and special histopathological findings
This case report presents an instance of Tumor Necrosis Factor-α Inhibitor-induced psoriasis (TNFiIP), also known as paradoxical psoriasis, in a 30-year-old male with fistulizing Crohn’s disease. The patient developed extensive erythematous and scaly lesions on the palms, lower limbs, ankles, and so...
Saved in:
Main Authors: | Fang Qiu, Weiquan Chen, Ying Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1507524/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
by: Selma Atalay, et al.
Published: (2022-07-01) -
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01) -
Efficacy of adalimumab in pediatric non-infectious uveitis with and without anterior segment inflammation
by: Chunbo Zhang, et al.
Published: (2025-01-01) -
New Possibilities for the Treatment of Crohn’s Disease
by: Z. A. Mamieva, et al.
Published: (2019-12-01) -
Adalimumab‐Induced Cutaneous Lupus Erythematosus: Cases Presenting With Malar Rash and Panniculitis
by: Parvin Mansouri, et al.
Published: (2025-01-01)